Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Show More...
-
Website http://www.corbuspharma.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 7.42 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.02 -0.13 -0.28 -0.49 -0.65 -0.98 -1.12 -1.12 Dividends USD Payout Ratio % * Shares Mil 26.0 20.0 31.0 41.0 50.0 57.0 64.0 66.0 Book Value Per Share * USD 0.27 0.3 0.29 0.58 0.75 0.46 0.31 Free Cash Flow Per Share * USD -0.05 -0.14 -0.24 -0.51 -0.49 -0.63 Return on Assets % -197.16 -73.57 -90.89 -130.02 -76.41 -97.7 -148.66 -89.89 Financial Leverage (Average) 1.13 1.43 2.01 1.16 1.71 7.98 2.87 Return on Equity % -124.55 -119.22 -223.4 -97.21 -130.52 -424.29 -230.41 Return on Invested Capital % -111.18 -116.82 -218.01 -96.88 -131.7 -281.61 -185.97 Interest Coverage -12.35 -104.76 Current Ratio 0.47 8.85 3.5 1.96 7.98 2.45 1.09 1.58 Quick Ratio 0.47 8.49 3.4 1.83 7.62 2.31 0.99 1.47 Debt/Equity 1.31 0.35